Kaiku Health is developed according to the principles of Evidence-Based Medicine.

Immune-checkpoint inhibitors (ICIs) have introduced novel immune-related adverse events (irAEs), arising from various organ systems without strong timely dependency on therapy dosing. Early detection of irAEs could result in improved toxicity profile and quality of life. Symptom data collected by electronic (e) patient-reported outcomes (PRO) could be used as an input for machine learning (ML) based prediction models for the early detection of irAEs. The purpose of the study is to investigate whether a ML-based prediction model for irAEs of cancer patients receiving ICIs could be created based on ePRO symptom data coupled with clinical data.

Patient-reported outcome (PRO) follow-up has been shown to improve quality of life (QoL) and survival of cancer patients receiving chemotherapy. Kaiku Health application is a web-based electronic PRO (ePRO) tool which is designed for follow-up of cancer patients receiving immune checkpoint inhibitors (ICI). Purpose of the current study is to investigate whether symptoms collected by Kaiku Health ePRO tool on cancer patients receiving immune checkpoint inhibitors (ICI) follows to symptoms reported in clinical trials and whether coupling of specific symptoms does occur.

The patient’s role in toxicity reporting is increasingly acknowledged. There is also a need for developing modern communication methods between the patient and the medical personnel. Furthermore, the increasing number of head and neck cancer (HNC) patients is reflected in the volume of treatment follow-up visits, which remains a challenge for the health care. Electronic patient-reported outcome (ePRO) measures may provide a cost-efficient way to organize follow-up for cancer patients.

Online calculator visualizes the risk of gastrointestinal stromal tumor (GIST) recurrence and helps the doctors to evaluate the need for additional treatment after surgery. GIST Risk calculator is based on a research containing an international sample of 2000 diagnosed GIST-patients published in 2012 by HUCH Cancer Center and Aalto University.